Literature DB >> 6395276

Comparison of cefonicid and cefazolin for treatment of soft-tissue infections.

G Slutkin, J Marzouk, L Dall, J Mills.   

Abstract

Cefonicid was compared with cefazolin for the treatment of serious infections of soft tissue. According to a randomized, prospective protocol designed to assign twice as many patients to cefonicid, 38 patients were treated with cefonicid and 19 patients, with cefazolin. Dosages used were 1.0 g once daily intramuscularly or intravenously for cefonicid and 0.5-1.0 g three times a day intramuscularly or intravenously for cefazolin. Clinical diagnoses included cellulitis (39 patients), abscesses (14), infected ulcers (3), and bursitis (1). Bacteriologic diagnoses included Staphylococcus aureus alone (8 patients), group A Streptococcus alone (13), combined S. aureus plus streptococci (8), viridans group streptococci alone (1), and mixed anaerobes (1). Gram-negative rods were isolated from 11 patients, all in mixed cultures with gram-positive species. For two patients, gram-negative organisms were thought to be etiologic. All 57 patients responded satisfactorily to treatment. Treatment with either drug was neither interrupted nor discontinued because of toxicity. Both cefonicid and cefazolin appear to be effective for the treatment of infections of skin and soft tissues. Cefonicid has the advantage of once-daily dosing.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6395276     DOI: 10.1093/clinids/6.supplement_4.s853

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  3 in total

1.  Antistaphylococcal activity of ceforanide and cefonicid in the presence of human serum.

Authors:  A L Barry; R N Jones; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

Review 2.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

3.  Randomized, double-blind trial of cefonicid and nafcillin in the treatment of skin and skin structure infections.

Authors:  J S Daly; M G Worthington; R J Andrews; R B Brown; R Schwartz; D J Sexton
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.